GSKs ADC Drug Gets FDAs Breakthrough Tag for Rare Bone Cancer
PBYI Stock | USD 3.55 0.19 5.08% |
Under 61% of Puma Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Puma Biotechnology suggests that many traders are alarmed. Puma Biotechnology's investing sentiment shows overall attitude of investors towards Puma Biotechnology.
Puma |
The FDA bestows a Breakthrough Therapy designation to GSKs antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
Read at zacks.com
Puma Biotechnology Fundamental Analysis
We analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Puma Biotechnology is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Puma Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Puma Biotechnology stock to make a market-neutral strategy. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics with similar companies.
Peers
Puma Biotechnology Related Equities
MDGL | Madrigal Pharmaceuticals | 3.14 | ||||
ARVN | Arvinas | 2.01 | ||||
SRPT | Sarepta Therapeutics | 1.43 | ||||
PTCT | PTC Therapeutics | 0.96 | ||||
RVMD | Revolution Medicines | 0.20 | ||||
MGNX | MacroGenics | 1.76 | ||||
RARE | Ultragenyx | 1.78 | ||||
CRNX | Crinetics Pharmaceuticals | 1.86 | ||||
VKTX | Viking Therapeutics | 2.54 | ||||
IOVA | Iovance Biotherapeutics | 3.11 | ||||
CHRS | Coherus BioSciences | 3.82 | ||||
LRMR | Larimar Therapeutics | 4.29 | ||||
TSVT | 2Seventy Bio | 4.61 | ||||
KURA | Kura Oncology | 4.77 | ||||
HRTX | Heron Therapeuti | 5.33 | ||||
HEPA | Hepion Pharmaceuticals | 8.20 |
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |